Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Instil Bio Inc TIL

Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. The Company seeks to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical need. Its first such program is an engineered tumor infiltrating lymphocyte (TIL), cell therapy for the treatment of cancer. It is engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor (CoStAR), platform. The Company's lead CoStAR-TIL product candidate, ITIL-306, expresses a CoStAR molecule designed to recognize folate receptor alpha (Fra), a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC and renal cancer. CAR-T and TCR-T therapies are cell products composed of T cells that have been genetically engineered to recognize a specific cancer-related antigen on the surface of tumor cells.


NDAQ:TIL - Post by User

Bullboard Posts
Comment by kaosblueson Feb 17, 2012 2:27pm
399 Views
Post# 19551016

RE: RE: RE: RE: RE: GPD hold

RE: RE: RE: RE: RE: GPD hold

Good post Scottie, the only thing I will add is that it is probable that the production decision has already been  made within the company and that is that they are going ahead.  Assuming this to be true then it was an obvious move to "lock up" the rest of the ownership of Brewery Creek because they see great value there.  Bill Sheriff has been hammering away about the extraordinary upside to the Brewery Creek play (and its extensions) for the past year.  It has been in virtually every presentation that he has made.  Purchasing the last 25% was not rocket science, as so many here would have us believe.  Indeed a case could probably have been made that it should have been done much earlier but we are not privy as to the reasons for the timing.  Perhaps they were looking at the totality of the data in preparation of the NI43 and it hit them in the forehead or perhaps there was an informal agreement to conclude this arrangement with AXR as close as possible to the release of a positive production decision. Ours is not to know these things unless Bill decides to be charitable with this information; but the important point here is that a decision has been made.To put it another way, it would be incomprehensible for them to turn around now and say they are not going ahead with production in light of this purchase.

I realize the above is a bit of a chicken and egg argument but be that as it may we are now sitting on a resource that very well may be a company maker. 62 cents a share is a steal of a deal in light of all we know about Brewery Creek and I believe that within a few short months there will be many kicking themselves all the way to Inuvik for not buying in or buying more at these levels.

Bullboard Posts